Table 1.
Basic Demographics of Control Subjects and Patients with PAH in Three Analysis Groups and More Detailed Clinical Characteristics, Including Disease Severity of Patients with PAH as a Cohort
| A: RNA Discovery | B: RNA Validation | C: Model Validation | ||||
|---|---|---|---|---|---|---|
| Control Subjects | PAH | Control Subjects | PAH | Control Subjects | PAH | |
| Female | 17 | 89 | 16 | 80 | 17 | 86 |
| Male | 7 | 31 | 8 | 40 | 7 | 33 |
| Age, yr | 43.9 (30.2–53.4) | 45.2 (35.7–55) | 45.1 (31–53.5) | 43.2 (33.3–54.8) | 44.4 (31.7–51.6) | 47.1 (36.7–61.2) |
| PAH Patient Characteristics in A, B, and C | Median (25th–75th Percentile) or Counts | |||||
|---|---|---|---|---|---|---|
| Age at diagnosis | 44.8 (34.3–58.1) | |||||
| Female/male |
255/104 |
|||||
| Ethnicity, white/other |
314/45 |
|||||
| WHO functional class, I/II/III/IV |
36/138/155/18 |
|||||
| Six-minute-walk distance, m |
330 (224.5–411) |
|||||
| Mean pulmonary artery pressure, mm Hg |
53 (46–61) |
|||||
| Mean right atrial pressure, mm Hg |
8 (6–12) |
|||||
| Pulmonary capillary wedge pressure, mm Hg |
10 (7–12) |
|||||
| Q̇, L/min |
3.8 (3.05–4.9) |
|||||
| Cardiac index, L/min/m2 |
2.07 (1.68–2.57) |
|||||
| Pulmonary vascular resistance, Wood units |
11.55 (7.93–15.78) |
|||||
| Years since diagnosis sampled |
3.95 (1.38–7.7) |
|||||
| Years survived since sampling |
3.14 (2.3–3.67) |
|||||
| Years survived since diagnosis |
6.99 (4.19–10.88) |
|||||
| Vasoresponders | 21 | |||||
Definition of abbreviations: PAH = pulmonary arterial hypertension; WHO = World Health Organization.
Control subjects are healthy volunteers without any cardiac or respiratory disease.